Disease details

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03126760 (ClinicalTrials.gov)	May 22, 2017	4/4/2017	Pilot Study to Assess the Efficacy & Safety of H.P. Acthar® Gel in Subjects With Relapsing-remitting Multiple Sclerosis	A Multicenter, Randomized, Double Blind, Placebo Controlled Parallel Group, Pilot Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Relapsing-remitting Multiple Sclerosis	Relapsing, Remitting Multiple Sclerosis	Drug: Repository Corticotropin Injection;Drug: Placebo	Mallinckrodt	NULL	Terminated	18 Years	N/A	All	35	Phase 4	United States
2	NCT01888354 (ClinicalTrials.gov)	April 2013	16/5/2013	Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ)Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations	Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ) Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations	Multiple Sclerosis (MS)	Drug: H.P. Acthar Gel (repository corticotropin injection)	The University of Texas Health Science Center, Houston	NULL	Completed	18 Years	55 Years	Both	25	Phase 4	United States
3	NCT00986960 (ClinicalTrials.gov)	December 2009	29/9/2009	Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)	Effect of Pulsed ACTH add-on Therapy to Weekly Avonex on Remyelination and Neuroregeneration in Patients With Relapsing Remitting Multiple Sclerosis. A 1-year Placebo-controlled, Double-blinded, Randomized Follow-up Study	Multiple Sclerosis	Drug: repository corticotropin injection;Drug: Saline	University at Buffalo	NULL	Terminated	18 Years	65 Years	All	3	Phase 2	United States